Aptinyx discovers and develops
innovative therapies for
challenging disorders of the brain and
nervous system.

nerve 650

Aptinyx's proprietary compounds modulate
the NMDA receptor,
a critical regulator
involved in nerve cell
communication.

Aptinyx seeks to leverage its experience and
track record of success to rapidly advance promising therapies in development for patients in need.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of transformative therapies for challenging neurologic disorders. Aptinyx has a proven platform for discovering compounds that work through a novel mechanism: modulation of NMDA receptors to enhance communication between neural cells.

Learn more about Aptinyx »

Latest News

June 10, 2019
Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain

May 14, 2019
Aptinyx Reports First Quarter 2019 Financial Results and Provides Corporate Update

May 7, 2019
Aptinyx Appoints Henry Gosebruch to Its Board of Directors

May 6, 2019
Aptinyx to Report First Quarter 2019 Financial Results on Tuesday, May 14, 2019

April 30, 2019
Aptinyx Reports Positive Data from Phase 1 Study of Novel NMDA Receptor Modulator, NYX-458, in Healthy Volunteers

See all press and news »